Reassessing the value of vaccines

Bärnighausen, Till; Berkley, Seth; Bhutta, Zulfiqar A; Bishai, David; Black, Maureen M.; Bloom, David E.; Constenla, Dagna; Driessen, Julia; Edmunds, John; Evans, David B.; Griffiths, Ulla K.; Hansen, Peter Toftedal; Hashmani, Farah Naz; Hutubessy, Raymond; Jamison, Dean T.; Jha, Prabhat; Jit, Mark; Johnson, Hope L.; Laxminarayan, Ramanan; Lee, Bruce Y.; Mhatre, Sharmila; Mills, Anne; Nordström, Anders; Ozawa, Sachiko; Prosser, Lisa A.; Silver, Karlee; Benn, Christine Stabell; Standaert, Baudouin; Walker, Damian

doi:10.1016/s2214-109x(13)70170-0

Cited by 54 publications

(36 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The value assessment of vaccines using ICUA has been most often performed using an approach similar to evaluation of treatments, expressing value as QALY gained or disability-adjusted life-year (DALY) avoided [47]. …”

Section: Defining Valuementioning

confidence: 99%

Towards a more comprehensive approach for a total economic assessment of vaccines?

Standaert

Rappuoli²

2017

Journal of Market Access & Health Policy

Self Cite

View full text Add to dashboard Cite

ABSTRACTSince we were born, we all take preventative actions to avoid unpredictable adverse conditions. Some actions are done automatically. Others require a conscious choice , either for personal or social benefit. A distinction can therefore be drawn between non-active and active prevention, and between individual and social prevention. Active prevention requires making a choice in time, effort, and cost. We call it an economic choice. Vaccines belong to the group of active and social prevention. Because a vaccination program is an economic social choice, how should it be valued, and what cost should we pay for? To date, the economic evaluations developed for treatment have been applied to vaccines. However, over 25 different characteristics differentiate vaccines from treatment. For example, the benefit of vaccination is measured at the population level not at the individual level, the main effect of prevention is societal and not an individual-based gain only, and the biggest hurdle to implement a new vaccine is the initial budget investment and not so much its estimated ‘value for money’. This makes the current application of incremental cost-utility analysis difficult for vaccines for a comprehensive evaluation. New approaches may be needed to capture the full economic benefit of vaccines.

show abstract

Section: Defining Valuementioning

confidence: 99%

Towards a more comprehensive approach for a total economic assessment of vaccines?

Standaert

Rappuoli²

2017

Journal of Market Access & Health Policy

Self Cite

View full text Add to dashboard Cite

show abstract

“…(14,(19)(20)(21)(22)(23)(24)(25)(26)(27). In this article, we argued that vaccination programs also have a special relationship with particular objectives of social policy.…”

Section: Resultsmentioning

confidence: 99%

The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness

Luyten

Beutels

2016

Health Affairs

View full text Add to dashboard Cite

“…It would also be useful to explore the distribution of vaccination's benefits among different possible beneficiaries. Third, the primary empirical evidence on broad vaccination benefits will need to be considerably expanded and improved (72). Although many studies have shown that these types of benefits can be substantial, for many benefit categories, the evidence base has not been firmly established.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, with respect to the goal of establishing broad vaccination benefits, a long time between exposure assignment and outcome assessment will likely be an advantage, because many of the broad benefits, such as school attainment and labor market outcomes, will only manifest themselves over longer periods of time. Collecting economic and social indicators as part of vaccination RCTs, or after the main trial has been completed, offers a promising and practical approach for guarding against the undervaluation bias that has plagued economic evaluation of vaccinations for decades (31,72). Observational studies can also be informative, especially insofar as they adjust statistically for nonrandom vaccination status using, for example, propensity score analysis or instrumental variables, or focus on within-family differences in vaccination status and related outcomes (33,55,57).…”

Section: Discussionmentioning

confidence: 99%

Valuing vaccination

Bärnighausen

Bloom

Cafiero-Fonseca

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

157

149

View full text Add to dashboard Cite

Vaccination has led to remarkable health gains over the last century. However, large coverage gaps remain, which will require significant financial resources and political will to address. In recent years, a compelling line of inquiry has established the economic benefits of health, at both the individual and aggregate levels. Most existing economic evaluations of particular health interventions fail to account for this new research, leading to potentially sizable undervaluation of those interventions. In line with this new research, we set forth a framework for conceptualizing the full benefits of vaccination, including avoided medical care costs, outcome-related productivity gains, behavior-related productivity gains, community health externalities, community economic externalities, and the value of risk reduction and pure health gains. We also review literature highlighting the magnitude of these sources of benefit for different vaccinations. Finally, we outline the steps that need to be taken to implement a broad-approach economic evaluation and discuss the implications of this work for research, policy, and resource allocation for vaccine development and delivery.benefit-cost analysis | immunization

show abstract

Reassessing the value of vaccines

Cited by 54 publications

References 6 publications

Towards a more comprehensive approach for a total economic assessment of vaccines?

Towards a more comprehensive approach for a total economic assessment of vaccines?

The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness

Valuing vaccination

Contact Info

Product

Resources

About